扩展了含有 [1,2,5]oxadiazolo[3,4-b]pyrazine 的素辅助剂的结构-活性关系研究
Susan L Harris1, Somnath Dutta1, Nianzi Liu1
1Department of Chemistry, Boulder, CO 80309, USA.
Bioorganic & medicinal chemistry letters
|October 31, 2024
概括
研究人员发现了新的化合物,使最后的抗生素再次有效地对抗药物耐药的阴性细菌. 这些新型胆固醇增强剂具有低毒性,为抗击具有挑战性的感染提供了希望.
科学领域:
- 微生物学 微生物学
- 药用化学 医学化学
- 传染性疾病 传染性疾病
背景情况:
- 抗菌素耐药性 (AMR) 是一个关键的全球健康威胁,特别是多药耐药性 (MDR) 格拉姆阴性细菌感染.
- 作为最后一种抗生素的胆固醇抗生素面临着日益增长的耐药性,限制了严重感染的治疗选择.
- 现有的治疗方法越来越无效,需要新的治疗策略.
研究的目的:
- 发现和开发新的胆固醇辅助剂,恢复抗生素对MDR阴性细菌的疗效.
- 为了研究[1,2,5]oxadiazolo[3,4-b]pyrazine (ODP) 类似物作为素增强剂的结构-活性关系 (SAR).
- 为了识别具有强大的抗微生物活性和低哺乳动物毒性的化合物.
主要方法:
- 对[1,2,5]oxadiazole[3,4-b]pyrazine (ODP) 衍生物进行查,以检测其对胆固醇敏感的活性.
- 广泛的结构-活性关系 (SAR) 研究ODP类似物与基或阿里基胺替代物.
- 对一系列临床相关的MDR格兰氏阴性病原体的化合物疗效的评估.
- 对有前途的辅助剂候选者的哺乳动物毒性评估.
主要成果:
- 发现了一系列比萨尼利诺ODP化合物,作为有效的胆固醇辅助剂.
- 鉴定了两种新型ODP类似物,5q和8g化合物,这些化合物表现出强大的胆固醇激活活性.
- 对已识别的基于ODP的素增强剂的低哺乳动物毒性证明.
- 新化合物对各种MDR格兰氏阴性细菌的广泛疗效.
结论:
- 新的[1,2,5]oxadiazolo[3,4-b]pyrazine (ODP) 类型可以有效地增强对抗多药性耐药性格拉姆阴性细菌的胆固醇.
- 化合物5q和8g代表了对抗具有挑战性的细菌感染的辅助疗法的有希望的候选人.
- 开发的基于ODP的化合物为日益严重的抗菌素耐药性危机提供了潜在的解决方案,具有有利的安全性.
更多相关视频
13:47Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Published on: May 19, 2020
3.4K
09:20Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay
Published on: April 28, 2014
12.6K
相关概念视频
01:28Structure-Activity Relationships and Drug Design
611
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
611
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.6K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.6K
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
526
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
526